Response to renal function in primary aldosteronism: Is glomerular hyperfiltration a hallmark of primary aldosteronism? Further results from the Primary Aldosteronism Prevalence in Hypertension (PAPY) study [4]

Hypertension

Volumn 48, Issue 6, 2006, Pages

  Rossi, Gian Paolo ^a   Mantero, Franco ^a   Pessina, Achille Cesare ^a  

^a Padova Department of Clinical and Experimental Medicine Internal Medicine 4   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; EPLERENONE; MINERALOCORTICOID ANTAGONIST; RENIN; SODIUM; SPIRONOLACTONE;

ADRENALECTOMY; ALDOSTERONE RELEASE; CREATININE CLEARANCE; DISEASE ASSOCIATION; GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; GLOMERULUS FILTRATION RATE; HISTOPATHOLOGY; HUMAN; HYPERTENSION; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY INJURY; LETTER; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; SODIUM INTAKE;

EID: 33751112704     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.0000245661.38264.d3     Document Type: Letter

References (13)

1. Sechi LA. Renal function in primary aldosteronism. Hypertension. 2006;48:e110.
2. Rossi GP, Bernini G, Desideri G, Fabris B, Ferri C, Giacchetti G, Letizia C, Maccario M, Mannelli M, Matterello MJ, Montemurro D, Palumbo G, Rizzoni D, Rossi E, Pessina AC, Mantero F, for the PAPY Study Participants. Renal damage in primary aldosteronism: results of the PAPY Study. Hypertension. 2006;48:232-238.
3. Ribstein J, du CG, Fesler P, Mimran A. Relative glomerular hyperfiltration in primary aldosteronism. J Am Soc Nephrol. 2005;16:1320-1325.
4. Sechi LA, Novello M, Lapenna R, Baroselli S, Nadalini E, Colussi GL, Catena C. Long-term renal outcomes in patients with primary aldosteronism. JAMA. 2006;295:2638-2645.
5. Rossi GP, Bernini G, Caliumi C, Desideri GB, Fabris B, Ferri C, Ganzaroli C, Giacchetti G, Letizia C, Maccario M, Mallamaci F, Mannelli M, Mattarello MJ, Moretti A, Palumbo G, Parenti G, Porteri E, Semplicini A, Rizzoni D, Rossi E, Boscaro M, Pessina AC, Mantero F, for the PAPY Study Investigators. A prospective study of the prevalence of primary aldosteronism in 1125 Hypertensive patients. J Am Coll Cardiol. In press.
6. Seccia TM, Rossi GP. Clinical use and pathogenetic basis of laboratory tests for the evaluation of primary arterial hypertension. Crit Rev Clin Lab Sci. 2005;42:393-452.
7. Pimenta E, Calhoun DA. Aldosterone, dietary salt, and renal disease. Hypertension. 2006;48:209-210.
8. Hall JE, Granger JP, Smith MJ Jr, Premen AJ. Role of renal hemodynamics and arterial pressure in aldosterone "escape." Hypertension. 1984;6:I183-I192.
9. Rocha R, Stier CT Jr, Kifor I, Ochoa-Maya MR, Rennke HG, Williams GH, Adler GK. Aldosterone: a mediator of myocardial necrosis and renal arteriopathy. Endocrinology. 2000;141:3871-3878.
10. Seccia TM, Belloni AS, Guidolin D, Sticchi D, Nussdorfer GG, Pessina AC, Rossi GP. The renal antifibrotic effects of angiotensin-converting enzyme inhibition involve bradykinin B2 receptor activation in angiotensin II-dependent hypertension. J Hypertens. 2006;24:1419-1427.
11. Rossi GP, Sacchetto A, Pavan E, Palatini P, Graniero GR, Canali C, Pessina AC. Remodeling of the left ventricle in primary aldosteronism due to Conn's adenoma. Circulation. 1997;95:1471-1478.
12. Rossi GP. Cardiac consequences of aldosterone excess in human hypertension. Am J Hypertens. 2006;19:10-12.
13. Rossi G, Boscaro M, Ronconi V, Funder JW. Aldosterone as a cardiovascular risk factor. Trends Endocrinol Metab. 2005;16:104-107.